title: Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release.
abstract: Inhibitors of monoamine oxidase (MAO) were initially used in medicine following the discovery of their antidepressant action. Subsequently their ability to potentiate the effects of an indirectly-acting sympathomimetic amine such as tyramine was discovered, leading to their limitation in clinical use, except for cases of treatment-resistant depression. More recently, the understanding that: a) potentiation of indirectly-acting sympathomimetic amines is caused by inhibitors of MAO-A but not by inhibitors of MAO-B, and b) that reversible inhibitors of MAO-A cause minimal tyramine potentiation, has led to their re-introduction to clinical use for treatment of depression (reversible MAO-A inhibitors and new dose form MAO-B inhibitor) and treatment of Parkinson's disease (MAO-B inhibitors). The profound neuroprotective properties of propargyl-based inhibitors of MAO-B in preclinical experiments have drawn attention to the possibility of employing these drugs for their neuroprotective effect in neurodegenerative diseases, and have raised the question of the involvement of the MAO-mediated reaction as a source of reactive free radicals. Despite the long-standing history of MAO inhibitors in medicine, the way in which they affect neuronal release of monoamine neurotransmitters is still poorly understood. In recent years, the detailed chemical structure of MAO-B and MAO-A has become available, providing new possibilities for synthesis of mechanism-based inhibitors. This review describes the latest advances in understanding the way in which MAO inhibitors affect the release of the monoamine neurotransmitters dopamine, noradrenaline and serotonin (5-HT) in the CNS, with an accent on the importance of these effects for the clinical actions of the drugs.
authors.affiliation: Rappaport Family Faculty of Medicine, Technion, Haifa, Israel. Electronic address: Finberg@tx.technion.ac.il.
authors.forename: John P M
authors.initials: JP
authors.lastname: Finberg
mesh_terms: D000928:Antidepressive Agents / Q000494:pharmacology*; D015306:Biogenic Monoamines / Q000378:metabolism*; D001921:Brain / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000145:classification / Q000494:pharmacology*; D018696:Neuroprotective Agents / Q000494:pharmacology*; D009638:Norepinephrine / Q000378:metabolism; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology; D012701:Serotonin / Q000378:metabolism; D009435:Synaptic Transmission / Q000502:physiology*
chemical_list: D000928:Antidepressive Agents; D015306:Biogenic Monoamines; D008996:Monoamine Oxidase Inhibitors; D018696:Neuroprotective Agents; D012701:Serotonin; D004298:Dopamine; D009638:Norepinephrine
keywords: Affective disorders; Enzyme active site structure; Exocytotic and non-exocytotic release; Neuroprotection; Parkinson's disease; Presynaptic inhibition